A novel approach to target inflammatory diseases

A novel approach to target inflammatory diseases

frenchtech-wht

Inotrem is an advanced clinical stage biotechnology company specialized in immunotherapy. The company has developed a new concept of immunomodulation that targets the TREM-1 pathway to control unbalanced inflammatory responses.

Inotrem_Picto Trem 1

Inotrem identified the TREM-1 pathway as a key factor in unbalanced inflammatory responses. The company focuses on the therapeutic and diagnostic tools derived from its knowledge of the biology of TREM-1 pathway.

Inotrem_Picto Pipeline

Inotrem conducts clinical programs using nangibotide for the treatment of acute inflammatory diseases such as septic shock and COVID-19. It also targets chronic inflammatory diseases through a broad anti-TREM monoclonal antibody program.

Inotrem_Picto Trem 1

INOTREM SA is a biopharmaceutical company discovering and developing first-in-class immunotherapies for the treatment of inflammatory diseases.

Inotrem_Picto Pipeline

A first clinical trial to assess the safety, tolerability and pharmacokinetics of MOTREM in healthy volunteers is currently ongoing.